Pancreatic β-Cell Function and Prognosis of Nondiabetic Patients With Ischemic Stroke

Stroke. 2017 Nov;48(11):2999-3005. doi: 10.1161/STROKEAHA.117.018203. Epub 2017 Sep 27.

Abstract

Background and purpose: Pancreatic β-cell dysfunction is an important factor in the development of type 2 diabetes mellitus. This study aimed to estimate the association between β-cell dysfunction and prognosis of nondiabetic patients with ischemic stroke.

Methods: Patients with ischemic stroke without a history of diabetes mellitus in the ACROSS-China (Abnormal Glucose Regulation in Patients with Acute Stroke across China) registry were included. Disposition index was estimated as computer-based model of homeostatic model assessment 2-β%/homeostatic model assessment 2-insulin resistance based on fasting C-peptide level. Outcomes included stroke recurrence, all-cause death, and dependency (modified Rankin Scale, 3-5) at 12 months after onset.

Results: Among 1171 patients, 37.2% were women with a mean age of 62.4 years. At 12 months, 167 (14.8%) patients had recurrent stroke, 110 (9.4%) died, and 184 (16.0%) had a dependency. The first quartile of the disposition index was associated with an increased risk of stroke recurrence (adjusted hazard ratio, 3.57; 95% confidence interval, 2.13-5.99) and dependency (adjusted hazard ratio, 2.30; 95% confidence interval, 1.21-4.38); both the first and second quartiles of the disposition index were associated with an increased risk of death (adjusted hazard ratio, 5.09; 95% confidence interval, 2.51-10.33; adjusted hazard ratio, 2.42; 95% confidence interval, 1.17-5.03) compared with the fourth quartile. Using a multivariable regression model with restricted cubic spline, we observed an L-shaped association between the disposition index and the risk of each end point.

Conclusions: In this large-scale registry, β-cell dysfunction was associated with an increased risk of 12-month poor prognosis in nondiabetic patients with ischemic stroke.

Keywords: diabetes mellitus; female; glucose; registries; stroke.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Ischemia / blood*
  • Brain Ischemia / diagnosis
  • Brain Ischemia / mortality*
  • C-Peptide / blood*
  • Fasting / blood
  • Female
  • Follow-Up Studies
  • Humans
  • Insulin Resistance*
  • Insulin-Secreting Cells / metabolism*
  • Male
  • Middle Aged
  • Models, Cardiovascular*
  • Prognosis
  • Registries*
  • Stroke / blood*
  • Stroke / diagnosis
  • Stroke / mortality*

Substances

  • C-Peptide